Olema posts Phase 1/2 data for lead asset in breast cancer
https://seekingalpha.com/news/4043544-olema-stock-falls-after-data-lead-asset-breast-cancer?source=feed_sector_healthcare
Dec 05, 2023 - Olema Pharmaceuticals (OLMA) announces interim results from a Phase 1b/2 clinical study for its breast cancer drug palazestrant. Read more here.
0
Nasdaq Showing Strong Move Back To The Upside, Dow Posting Modest Gain
https://www.rttnews.com/story.aspx?Id=3410250
Dec 07, 2023 - Stocks have moved mostly higher during trading on Thursday, rebounding following the downturn seen over the course of the previous session. The major averages have all moved to the upside, with the tech-heavy Nasdaq leading the advance. The strength on Wall Street may partly reflect ongoing optimism about the outlook for interest rates ahead of the release of the closely watched jobs report.
0
TUA: Revisiting Post December FOMC, Upgrade To Buy
https://seekingalpha.com/article/4658171-tua-revisiting-post-december-fomc-upgrade-to-buy?source=feed_tag_etf_portfolio_strategy
Dec 15, 2023 - TUA looks fairly priced in a 'soft landing' scenario, especially when the Fed recently suggested peak short-term rates have been reached. Read more here.
0
U.S. Stocks Give Back Ground But Still Post Substantial Gains For The Year
https://www.rttnews.com/story.aspx?Id=3414014
Dec 29, 2023 - Following the lackluster performance seen in recent sessions, stocks fluctuated over the course of the trading session on Friday before ending the day mostly lower. The major averages still posted substantial gains for the year. The Nasdaq skyrocketed by 43.4 percent, the S&P 500 soared by 24.2 percent and the Dow surged by 13.7 percent.
0
Post Holdings: Shift To Pet Food Should Benefit Shares In 2024
https://seekingalpha.com/article/4661053-post-holdings-shift-to-pet-food-should-benefit-shares-2024?source=feed_all_articles
Jan 03, 2024 - Post Holdings is facing sluggish demand but is enhancing margins through M&A strategy and increasing pet exposure. Read why POST stock is a Buy.
0
Nasdaq Remains Sharply Lower But Dow Posting Modest Gain
https://www.rttnews.com/story.aspx?Id=3414261
Jan 02, 2024 - After coming under pressure early in the session, stocks have regained some ground over the course of the trading day on Tuesday but remain mostly lower. The tech-heavy Nasdaq continues to post a particularly steep loss.
0
Ken Griffin’s hedge fund Citadel posts double-digit returns in 2023, but lags the S&P 500
https://www.cnbc.com/2024/01/04/ken-griffins-hedge-fund-citadel-posts-double-digit-returns-in-2023-but-lags-the-broader-market.html
Jan 04, 2024 - Billionaire investor Ken Griffin's various hedge fund strategists all posted double-digit returns for 2023, but they failed to beat the broader market.
0
Equity Funds Post Their Best Quarterly Returns Since 2020 For Q4 2023
https://seekingalpha.com/article/4661761-equity-funds-post-their-best-quarterly-returns-since-2020-for-q4-2023?source=feed_tag_etf_portfolio_strategy
Jan 08, 2024 - Equity funds outshine in Q4 2023 with impressive gains, led by Lipper's World Sector Equity Funds. Click here to read our most recent update.
0
Regeneron to post over $1.3B U.S. Eylea sales in Q4
https://seekingalpha.com/news/4053188-regeneron-stock-lower-after-early-eylea-sales?source=feed_sector_healthcare
Jan 08, 2024 - Regeneron Pharmaceuticals (REGN) released its early Q4 2023 financials, disclosing over $1.3B U.S. sales from its eye disease therapy Eylea. Read more here.
0
BlackRock TCP Capital: Potential To Be A Major Player In The BDC Space Post-Merger?
https://seekingalpha.com/article/4661442-blackrock-tcp-capital-potential-to-be-a-major-player-in-the-bdc-space-post-merger?source=feed_tag_editors_picks
Jan 08, 2024 - BlackRock TCP Capital announced a merger with BlackRock Capital Investment. Read why the merger is expected to create long-term value for shareholders.
0
Page 1>